Pembrolizumab monotherapy, in particular, has demonstrated superior efficacy and tolerability compared to standard chemotherapy for the treatment of metastatic non-oncogene-addicted NSCLC patients with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% [5]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.